IP Library Granted Patent US 10,379,129
Granted Patent B2
US 10,379,129 · App. 15/287,301 · Granted Aug 13, 2019

Antibodies to paliperidone and use thereof

Inventors: Eric Hryhorenko (Hilton, NY); Banumathi Sankaran (Lexington, MA); Thomas R. DeCory (Pittsford, NY); Theresa Tubbs (Rochester, NY); Linda Colt (Rochester, NY); Maarten Vliegen (Rijkevorsel, BE); Pieter Rik Haspeslagh (Halen, BE)
Assignee: Janssen Pharmaceutica NV
G01N33/9413C07K16/44G01N33/9406C07K2317/33C07K2317/56C07K2317/565
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,379,129
App. No.
15/287,301
Granted
Aug 13, 2019
Kind
B2
Abstract

Disclosed is an antibody which binds to paliperidone, which can be used to detect paliperidone in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of paliperidone, including multiplex detection of aripiprazole, quetiapine, olanzapine, and risperidone/paliperidone in a single lateral flow assay device.

Claims (15)

1. An isolated antibody or a binding fragment thereof, which specifically binds to paliperidone comprising a light chain variable region comprising CDR1, CDR2 and CDR3 of SEQ ID NO:3, and a heavy chain variable region comprising CDR1, CDR2 and CDR3 of SEQ ID NO:4, wherein the light chain CDR1 sequence comprises amino acid residues 44 to 60 of SEQ ID NO:3; the light chain CDR2 sequence comprises amino acid residues 76 to 82 of SEQ ID NO:3; the light chain CDR3 sequence comprises amino acid residues 115 to 123 of SEQ ID NO:3; the heavy chain CDR1 sequence comprises amino acid residues 45 to 54 of SEQ ID NO:4; the heavy chain CDR2 sequence comprises amino acid residues 69 to 85 of SEQ ID NO:4; and the heavy chain CDR3 sequence comprises amino acid residues 118 to 122 of SEQ ID NO:4.

2. The isolated antibody or a binding fragment thereof of claim 1 , wherein the antibody fragment is selected from the group of fragments consisting of Fv, F(ab′), F(ab′)2, scFv, minibody and diabody fragments.

3. The isolated antibody of claim 1 , wherein the antibody is a monoclonal antibody.

4. An assay kit comprising the isolated antibody or a binding fragment thereof of claim 1 .

5. An assay device comprising the isolated antibody or a binding fragment thereof of claim 1 .

6. The assay device of claim 5 , wherein the device is a lateral flow assay device.

7. A method of detecting paliperidone in a sample, the method comprising:

(i) contacting a sample with the antibody or binding fragment thereof of claim 1 labeled with a detectable marker, wherein the labeled antibody or a binding fragment thereof and paliperidone present in the sample form a labeled complex; and

(ii) detecting the labeled complex, thereby detecting paliperidone in the sample.

8. A competitive immunoassay method for detecting paliperidone in a sample, the method comprising:

(i) contacting a sample with the antibody or binding fragment thereof of claim 1 , and with paliperidone or a competitive binding partner of paliperidone, wherein one of the antibody or binding fragment thereof and the paliperidone or competitive binding partner thereof is labeled with a detectable marker, and wherein sample paliperidone competes with the paliperidone or competitive binding partner thereof for binding the antibody or binding fragment thereof to form a complex; and

(ii) detecting the amount of label to detect sample paliperidone.

9. The method of claim 8 , wherein the paliperidone or competitive binding partner thereof is labeled with the detectable marker.

10. The method of claim 8 , wherein the antibody or binding fragment thereof is labeled with a detectable marker.

11. The method of claim 8 , wherein the immunoassay is performed on a lateral flow assay device and the sample is applied to the device.

Continuity (3)
Continuation 13971416 · Aug 20, 2013
Provisional Application 61691692 · Aug 21, 2012
Related Publication 20170045537A1 · Feb 16, 2017